Anbio Biotechnology Class A Ordinary Shares (NNNN) Revenue History
Annual and quarterly revenue from 2021 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NNNN Revenue Growth
NNNN Revenue Analysis (2021–2024)
As of May 6, 2026, Anbio Biotechnology Class A Ordinary Shares (NNNN) generated trailing twelve-month (TTM) revenue of $16.1 million, reflecting significant decline in growth of -36.0% year-over-year. The most recent quarter (Q4 2024) recorded $2.5 million in revenue, down 60.0% sequentially.
Looking at the longer-term picture, NNNN's historical revenue data shows a 3-year CAGR of +22.7%. The company achieved its highest annual revenue of $23.5 million in 2022.
When compared to Healthcare sector peers including CLOV (+40.3% YoY), ACHC (+6.8% YoY), and QDEL (-3.9% YoY), NNNN has underperformed the peer group in terms of revenue growth. Compare NNNN vs CLOV →
NNNN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NNNNCurrent | $16M | -36.0% | - | 24.4% | |
 CLOV | $1.9B | +40.3% | +23.4% | -4.4% | |
 ACHC | $3.3B | +6.8% | +9.7% | 11.7% | |
 QDEL | $2.7B | -3.9% | +10.4% | -33.7% | |
 IDXX | $4.3B | +13.1% | +9.7% | 31.6% |
NNNN Historical Revenue Data (2021–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $8.2M | +21.9% | $5.9M | 71.9% | $2.0M | 24.4% |
| 2023 | $6.7M | -71.5% | $3.4M | 50.1% | $2.0M | 29.2% |
| 2022 | $23.5M | +431.7% | $12.6M | 53.4% | $10.2M | 43.3% |
| 2021 | $4.4M | - | $2.5M | 57.4% | $2.5M | 55.5% |
See NNNN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NNNN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NNNN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNNNN — Frequently Asked Questions
Quick answers to the most common questions about buying NNNN stock.
Is NNNN's revenue growth accelerating or slowing?
NNNN revenue declined -36.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $16M. This reverses the prior growth trend.
What is NNNN's long-term revenue growth rate?
Anbio Biotechnology Class A Ordinary Shares's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -36.0% is below this long-term average.
How is NNNN's revenue distributed by segment?
NNNN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2021-2024 are available for download. Segment mix reveals concentration and diversification trends.